| Literature DB >> 31394827 |
Matteo Bonato1, Mariaenrica Tiné1, Erica Bazzan1, Davide Biondini1, Marina Saetta2, Simonetta Baraldo1.
Abstract
Asthma is a heterogeneous condition characterized by reversible airflow limitation, with different phenotypes and clinical expressions. Although it is known that asthma is influenced by age, gender, genetic background, and environmental exposure, the natural history of the disease is still incompletely understood. Our current knowledge of the factors determining the evolution from wheezing in early childhood to persistent asthma later in life originates mainly from epidemiological studies. The underlying pathophysiological mechanisms are still poorly understood. The aim of this review is to converge epidemiological and pathological evidence early in the natural history of asthma to gain insight into the mechanisms of disease and their clinical expression.Entities:
Keywords: bronchial biopsies; clinical remission; symptom persistence; wheezing
Year: 2019 PMID: 31394827 PMCID: PMC6723918 DOI: 10.3390/jcm8081180
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Biopsy sections from a child with asthma (A,C), and a control child (B,D). An increased number of subepithelial vessels (A, brown) and eosinophils (C, red) are demonstrated in the child with asthma. The arrows indicate loss of epithelial cells (A,C), while the arrowheads indicate reticular basement membrane thickening (A). Immunostaining with monoclonal antibody anti-CD31 (A,B) and anti-EG2 (C,D). Original magnification ×630. Reprinted with permission of the American Thoracic Society from [30].
Histopathologic changes in bronchial biopsies of asthmatic/wheezing children.
| Number of Children | Mean Age (years) | RBM Thickening | Epithelial Loss | SM Enlargement | Submucosal Inflammation | Angiogenesis | |
|---|---|---|---|---|---|---|---|
| Cutz 1978 [ | 4 | 12 (11–12) | + | 0 | + | Eos | / |
| Cokuğraş 2001 [ | 10 | 9.3 ± 3.8 | + | / | / | Ly | / |
| Jenkins 2003 [ | 6 | 13.5 (6–17) | + | / | + | Eos | / |
| Payne 2003 [ | 19 | 13 (6–16) | + | / | / | 0 | / |
| Barbato 2003 [ | 9 | 8 (4–12) | + | / | / | Eos | / |
| Payne 2004 [ | 36 | 13 (6–16) | + | / | / | 0 | / |
| Saglani 2005 [ | 16 | 1 (0.3–2) | 0 | / | / | 0 | / |
| Barbato 2006 [ | 17 | 5 (2–15) | + | + | / | Eos | + |
| Saglani 2007 [ | 16 | 2.4 (0.6–4.75) | + | / | / | Eos | / |
| Kim 2007 [ | 18 | 13 ± 1 | + | / | / | / | / |
| Regamey 2008 [ | 24 | 12.5 (6.7–15.8) | / | / | + | / | / |
| Zhou 2011 [ | 13 | 7.2 (1.5–15) | + | + | + | Ly | / |
| Bossley 2012 [ | 53 | 12 (9–14) | + | / | + | Eos | / |
| Berankova 2014 [ | 30 | 1 (0.3–3.3) | + | / | / | / | / |
| Van Mastrigt 2015 [ | 107 | 9.5 ± 4.6 | + | / | / | / | / |
Age is reported as median (range) or mean ± SD. Definition of abbreviations: Eos: eosinophils; Ly: lymphocytes; RBM: reticular basement membrane; SM: smooth muscle. Presence of the histological feature (+), absence (0), feature not evaluated in the study (/).
Figure 2Determinants of disease course across asthma transition and ages. The figure displays putative determinants that affect the disease course of different asthma phenotypes by course and time of onset of symptoms. AHR: airway hyper-responsiveness. Reprinted with permission from Elsevier from [5].